Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory
- PMID: 38997625
- PMCID: PMC11245767
- DOI: 10.1186/s12879-024-09593-6
Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory
Abstract
Background and purpose: The seroprevalence of antibodies against measles, mumps, and rubella (MMR) was evaluated 17 years following a mass vaccination campaign in individuals aged 2 to 22 years who had received routine immunization but were not eligible for an extended immunization program.
Methods: Samples were acquired from Iran's National Measles Laboratory (NML), with individuals showing positive IgM results excluded. Out of the samples collected in 2020, a random selection of 290 serum samples was chosen, representing individuals between the ages of 2 and 22 years from diverse regions in the country. These samples were subjected to analysis using an enzyme-linked immunosorbent assay (ELISA) to quantify specific IgG antibodies against MMR.
Results: The seroprevalence rates of antibodies for measles, mumps, and rubella were determined to be 76.2%, 89.3%, and 76.9%, respectively. Younger age groups exhibited higher seropositivity rates for measles and mumps, whereas the 7- to 11-year-old group demonstrated the highest seropositivity rate for rubella. A reduction in antibody status was observed from younger to older age groups, particularly those aged 17-22.
Conclusion: The study unveiled suboptimal antibody levels for measles and rubella, highlighting the necessity for further investigation and potential adjustments to future vaccination strategies. Moreover, the decline in antibody status post-vaccination can accumulate in seronegative individuals over time, elevating the risk of outbreaks.
Keywords: Antibody status; Measles; Mumps; Rubella; Seroprevalence; Vaccine.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, Bagheri Lankarani K. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS ONE. 2013;8(1):e55043. doi: 10.1371/journal.pone.0055043. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- 9711410006/School of Public Health, Tehran University of Medical Science
- 9711410006/School of Public Health, Tehran University of Medical Science
- 9711410006/School of Public Health, Tehran University of Medical Science
- 9711410006/School of Public Health, Tehran University of Medical Science
- 9711410006/School of Public Health, Tehran University of Medical Science
LinkOut - more resources
Full Text Sources
Medical